Actively Recruiting
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
Led by Oregon Health and Science University · Updated on 2025-03-06
141
Participants Needed
1
Research Sites
66 weeks
Total Duration
On this page
Sponsors
O
Oregon Health and Science University
Lead Sponsor
N
National Center for Advancing Translational Sciences (NCATS)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to compare the rate of treatment initiation achieved by peer-assisted telemedicine contingent on phlebotomy (usual care) versus that achieved with a new protocol, called Dried Blood Spot Test and Treat (DBS TaT). DBS TaT includes DBS testing to diagnose hepatitis C (HCV), utilizes a novel clinical decision aid that identifies patients who are low risk for hepatic (liver) fibrosis, and directs those patients to HCV treatment initiation prior to routine hepatic fibrosis assessment. The investigators hypothesize that DBS TaT will increase the rate of HCV treatment initiation compared to peer-assisted telemedicine contingent on phlebotomy (usual care).
CONDITIONS
Official Title
DBS TaT in Peer-assisted Telemedicine for Hepatitis C
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Active hepatitis C infection
- Willing to engaged with the PATHS program for clinical care
You will not qualify if you...
- Currently pregnant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Oregon Health & Science University
Portland, Oregon, United States, 97239
Actively Recruiting
Research Team
H
Hunter Spencer, DO
CONTACT
T
Tonhi Gailey
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here